Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2006-06-21
2010-12-07
Cheu, Jacob (Department: 1641)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007200, C436S518000
Reexamination Certificate
active
07846674
ABSTRACT:
The present invention relates to a method aiding in the assessment of rheumatoid arthritis. The method especially is used in assessing the absence or presence of rheumatoid arthritis in vitro. The method is for example practiced by analyzing biochemical markers, comprising measuring in a sample the concentration of anti-CCP and interleukin 6 and correlating the concentrations determined to the absence or presence of rheumatoid arthritis. To further improve the assessment of RA in a method of this invention the level of one or more additional marker may be determined together with anti-CCP and interleukin 6 and be correlated to the absence or presence of RA. The invention also relates to the use of a marker panel comprising anti-CCP and interleukin 6 in the diagnosis of rheumatoid arthritis and it teaches a kit for performing the method of the invention.
REFERENCES:
patent: 4208479 (1980-06-01), Zuk et al.
patent: 4755380 (1988-07-01), Grubb et al.
patent: 6017693 (2000-01-01), Yates, III et al.
patent: 6309888 (2001-10-01), Holvoet et al.
patent: 6410724 (2002-06-01), Dejean et al.
patent: 2002/0072492 (2002-06-01), Myers et al.
patent: 2003/0224386 (2003-12-01), Guild et al.
patent: 1107006 (2001-06-01), None
patent: 0654092 (2003-09-01), None
patent: WO 98/08946 (1998-03-01), None
patent: WO 98/22503 (1998-05-01), None
patent: WO 99/28344 (1999-06-01), None
patent: WO 99/35167 (1999-07-01), None
patent: WO 01/46222 (2001-06-01), None
patent: WO 01/94616 (2001-12-01), None
patent: WO 02/06840 (2002-01-01), None
patent: WO 02/23200 (2002-03-01), None
patent: WO 02/48310 (2002-06-01), None
patent: WO 03/050542 (2003-06-01), None
patent: WO 03/060465 (2003-06-01), None
patent: WO 03/069341 (2003-08-01), None
patent: WO 2005029091 (2005-03-01), None
Leeuwen et al. (Annals Rheumatic Disease 1996 vol. 54, p. 674-677.
Schellekens et al. (Arthritis & Rheumatism 2000 vol. 43, p. 155-163).
J. Clinical Laboratory Analysis 2000 vol. 14, p. 305-313.
Liao et al. Hepatobiliary Pancreat Dis Int. 2007 vol. 6, p. 641-645.
Landers et al. Int. J. Cancer 2005 vol. 114, p. 950-956.
Swaak et al. (J. Scan. Rheumatol. 1988 vol. 469-474.
An Introduction to Classification Regression Tree Analysis ( by Lewis, PhD. presentation date 2000 at the annul meeting for the society of emergency medicine; p. 1-14.
Madhok et al. Annals Rheumatic Diseases 1993 vol. 52, p. 232-234.
Migita et al. Lab. Investigation 1998 vol. 78, p. 535-539.
McLachlan, G., “Discriminant Analysis and Statistical Pattern Recognition”, bibliographic data, John Wiley & Sons, Inc., 1992.
Al-Dehaimi, A. et al., “Serum Galactosyl Hydroxylysine as a Biochemical Marker of Bone Resorption,” Clinical Chemistry 45:5, 676-681 (1999).
Arnett, F. et al., “The American Rheumatism Association 1987 Revised Criteria for the Classification of Rheumatoid Arthritis,” Arthritis and Rheumatism, vol. 31, No. 3 (Mar. 1988) 315-324.
Ballara, S. et al., “Raised Serum Vascular Endothelial Growth Factor Levels are Associated with Destructive Change in Inflammatory Arthritis,” Arthritis & Rheumatism, vol. 44, No. 9, Sep. 2001, 2055-2064.
Bartfield, H. et al., “Distribution of Rheumatoid Factor Activity in Nonrheumatoid States,” Ann. NY Acad. Sci. 168(1969) 30-40.
Bas, S. et al., “Comparative study of different enzyme immunoassays for measurement of IgM and IgA rheumatoid factors,” Ann Rehum Dis 2002; 61, 505-510.
Bas, S. et al., “Diagnostic tests for rheumatoid arthritis: comparison of anti-cyclic citrullinated peptide antibodies, anti-keratin antibodies and IgM rheumatoid factors,” Rheumatology 2002; 41: 809-814.
Billinghurst, R. et al., “Enhanced Cleavage of Type II Collagen by Collagenases in Osteoarthritic Articular Cartilage,” J. Clin. Invest. 99 (1997)1534-1545.
Bizzaro, N. et al., “Diagnostic Accuracy of the Anti-Citrulline Antibody Assay for Rheumatoid Arthritis,” Clinical Chemistry, 47:6, 1089-1093 (2001).
Bonde, M. et al., “Immunoassay for Quantifying Type I Collagen Degradation Products in Urine Evaluated,” Clin.Chem. 40/11, 2022-2025 (1994).
Breiman, L.,“Random Forests,” Machine Learning, 45, 5-32, 2001.
Brenchley, P. et al., “Angiogenesis in inflammatory joint disease: a target for therapeutic intervention,” Clin Exp Immunol 2000, 121:426-429.
Burmeister, G. et al., “A Selective Method for Determining MRP8 and MRP14 Homocomplexes and Heterocomplexes by Sandwich Elisa for the Discrimination of Active and Non-Active Osteoarthritis from Rheumatoid Arthritis in Sera and Synovial Fluids,” Inflammapharmacology, 1995; 3: 221-230.
Chabas, D. et al., “The Influence of the Proinflammatory Cytokine, Ostopontin, on Autoimmune Demyelinating Disease,” Science, vol. 294, Nov. 23, 2001, 1731-1735.
Foell, D. et al., “Expression of the pro-inflammatory protein S100Al2 (EN-RAGE) in rheumatoid and psoriatic arthritis,” Rheumatology, 2003; 42:1383-1389.
Friedman, J., “Regularized Discriminant Analysis,” Journal of the American Statistical Association, Mar. 1989, 165-175.
Gineyts, E., “Urinary excretion of glucosyl-galactosyl pyridinoline: a specific biochemical marker of synovium degradation,” Rheumatology 2001; 40:315-323.
Gundberg, C., “Biology, Physiology, and Clinical Chemistry of Osteocalcin,” Journal of Clinical Ligand Assay, vol. 21, No. 2, Summer 1998.
Hochberg, M. et al., “The American College of Rheumatology 1991 Revised Criteria for the Classification of Global Functional Status in Rheumatoid Arthritis,” Arthritis and Rheumatism, vol. 35, No. 5 (May 1992) 498-502.
Ishiguro, N. et al., “Relationships of Matrix Metalloproteinases and Their Inhibitors to Cartilage Proteoglycan and Collagen Turnover and Inflammation as Revealed by Analyses of Synovial Fluids from Patients with Rheumatoid Arthritis,” Arthritis & Rheumatism, vol. 44, No. 11, Nov. 2001, pp. 2503-2511.
Johansen, J. et al., “Serum YKL-40 concentrations in patients with early rheumatoid arthritis: relation to joint destruction,” Scand J Rheumatol 2001; 30: 297-304.
Jorgensen, C. et al., “IgA isotype rheumatoid factor in rheumatoid arthritis: clinical implications,” Clinical and Experimental Rheumatology 14: 301-304, 1996.
Kaufmann, J. et al., “Hydroxypyridinium collagen crosslinks in serum, urine, synovial fluid and synovial tissue in patients with rheumatoid arthritis compared with osteoarthritis,” Rheumatology 2004; 42: 314-320.
Kellgren, J. et al., “Radiological Assessment of Osteo-Arthritis,” Ann. Rheum. Dis (1957) 16,494-502.
Knott, L. et al., “Collagen Cross-Links in Mineralizing Tissues: A Review of Their Chemistry, Function and Clinical Relevance,” Bone vol. 22, No. 3, Mar. 1998: 181-187.
Lee, S. et al., “Vascular endothelial growth factor levels in the serum and synovial fluid of patients with rheumatoid arthritis,” Clinical and Experimental Rheumatology: 2001; 19: 321-324.
Lorenzo, P. et al., “A Novel Cartilage Protein (CILP) Present in the Mid-Zone of Human Articular Cartilage with Age,” The Journal of Biological Chemistry, vol. 273, No. 36, Sep. 4, 1998, 23463-23468.
Moore, T. et al., “Rheumatoid Factors,” Clin. Biochem., vol. 26, pp. 75-84, 1993.
Muller-Ladner, U. et al., “MIA (melanoma inhibitory activity): a potential serum marker for rheumatoid arthritis,” Rheumatology 1999; 38:148-158.
Petrow, P. et al., “Expression of Osteopontin Messenger RNA and Protein in Rheumatoid Arthritis,” Arthritis & Rheumatism, vol. 43, No. 7, Jul. 2000, p. 1597-1605.
Rantapaa-Dahlqvist, S. et al., “Antibodies Against Cyclic Citrullinated Peptide and IgA Rheumatoid Factor Predict the Development of Rheumatoid Arthritis,” Arthiritis & Rheumatism, vol. 48, No. 10, Oct. 2003, pp. 2741-2749 .
Ruczinski, I. et al., “Logic Regression,” Journal of
Grunert Viet Peter
Karl Johann
Wild Norbert
Zolg Werner
Cheu Jacob
Roche Diagnostics Operations Inc.
LandOfFree
Assessing rheumatoid arthritis by measuring anti-CCP and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Assessing rheumatoid arthritis by measuring anti-CCP and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Assessing rheumatoid arthritis by measuring anti-CCP and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4227167